Compositions and methods for enrichment of neural stem cells using ceramide analogs
First Claim
1. A method of producing a human neural cell comprising,a) providing a pluripotent human cell;
- andb) culturing the pluripotent human cell with a composition comprising a ceramide compound selected from the group consisting of N-(2-hydroxy-1-(hydroxymethyl)ethyl)-palmitoylamide (“
S16”
), N-(2-hydroxy-1-(hydroxymethyl)ethyl)-oleoylamide (“
S18”
), N,N-bis(2-hydroxyethyl)palmitoylamide (“
B16”
), N,N-bis(2-hydroxyethyl)oleoylamide (“
B18”
) N-tris(hydroxymethyl)methyl-palmitoylamide (“
T16”
), N-tris(hydroxymethyl)methyl-oleoylamide (“
T18”
), N-acetyl sphingosine (“
C2-ceramide”
), and N-hexanoylsphingosine (“
C6-ceramide”
) to produce the human neural cell.
7 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.
-
Citations
20 Claims
-
1. A method of producing a human neural cell comprising,
a) providing a pluripotent human cell; - and
b) culturing the pluripotent human cell with a composition comprising a ceramide compound selected from the group consisting of N-(2-hydroxy-1-(hydroxymethyl)ethyl)-palmitoylamide (“
S16”
), N-(2-hydroxy-1-(hydroxymethyl)ethyl)-oleoylamide (“
S18”
), N,N-bis(2-hydroxyethyl)palmitoylamide (“
B16”
), N,N-bis(2-hydroxyethyl)oleoylamide (“
B18”
) N-tris(hydroxymethyl)methyl-palmitoylamide (“
T16”
), N-tris(hydroxymethyl)methyl-oleoylamide (“
T18”
), N-acetyl sphingosine (“
C2-ceramide”
), and N-hexanoylsphingosine (“
C6-ceramide”
) to produce the human neural cell. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- and
-
10. A method of producing a human neural cell comprising,
a) providing a pluripotent human cell; - and
b) culturing the pluripotent human cell with a composition comprising a ceramide compound of the structure
- and
-
11. A method of producing a human neural cell comprising,
a) providing a pluripotent human cell; - and
b) culturing the pluripotent human cell with a composition comprising a ceramide compound of the structure
- and
Specification
-
- Resources
-
Current AssigneeMedical College of Georgia (University System of Georgia), Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
-
Original AssigneeMedical College of Georgia (University System of Georgia), Bresagen, Inc. (Vertex Pharmaceuticals Incorporated)
-
InventorsBieberich, Erhard, Condie, Brian G.
-
Primary Examiner(s)Romeo; David S
-
Assistant Examiner(s)Gamett; Daniel C
-
Application NumberUS10/529,115Publication NumberTime in Patent Office1,867 DaysField of SearchNoneUS Class Current435/377CPC Class CodesA61P 25/16 Anti-Parkinson drugsC12N 2500/34 SugarsC12N 2500/36 LipidsC12N 2500/90 Serum-free medium, which ma...C12N 2502/14 hepatocytesC12N 2506/02 from embryonic cellsC12N 5/0618 Cells of the nervous systemC12N 5/0619 Neurons
